Uncovering a Novel 51A Mutation and Antifungal Resistance in Through Culture Collection Screening

Background: is an important concern for immunocompromised individuals, often resulting in severe infections. With the emergence of resistance to azoles, which has been the therapeutic choice for infections, monitoring the resistance of these microorganisms becomes important, including the search for mutations in the 51A gene, which is the gene responsible for the mechanism of action of azoles. We conducted a retrospective analysis covering 478 isolates.

Methods: This comprehensive dataset comprised 415 clinical isolates and 63 isolates from hospital environmental sources. For clinical isolates, they were evaluated in two different periods, from 1998 to 2004 and 2014 to 2021; for environmental strains, one strain was isolated in 1998, and 62 isolates were evaluated in 2015. Our primary objectives were to assess the epidemiological antifungal susceptibility profile; trace the evolution of resistance to azoles, Amphotericin B (AMB), and echinocandins; and monitor 51A mutations in resistant strains. We utilized the broth microdilution assay for susceptibility testing, coupled with 51A gene sequencing and microsatellite genotyping to evaluate genetic variability among resistant strains.

Results: Our findings reveal a progressive increase in Minimum Inhibitory Concentrations (MICs) for azoles and AMB over time. Notably, a discernible trend in 51A gene mutations emerged in clinical isolates starting in 2014. Moreover, our study marks a significant discovery as we detected, for the first time, an isolate carrying the recently identified TR46/F495I mutation within a sample obtained from a hospital environment. The observed 51A mutations underscore the ongoing necessity for surveillance, particularly as MICs for various antifungal classes continue to rise.

Conclusions: By conducting resistance surveillance within our institution's culture collection, we successfully identified a novel TR46/F495I mutation in an isolate retrieved from the hospital environment which had been preserved since 1998. Moreover, clinical isolates were found to exhibit TR34/L98H/S297T/F495I mutations. In addition, we observed an increase in MIC patterns for Amphotericin B and azoles, signaling a change in the resistance pattern, emphasizing the urgent need for the development of new antifungal drugs. Our study highlights the importance of continued monitoring and research in understanding the evolving challenges in managing infections.